*Purpose: US veterans are less likely to be transplanted. This disparity is related to donor shortage. This study seeks to increase access to transplant of US veterans to transplants using covid+ organs. This provides high quality organs to underserved population, reduce discards and is safe. Report of safety of this strategy. Early reports demonstrates safety in using these organs.

*Methods: Case presentation of two veterans transplanted with covid+ organs. Recipient and donor characteristics highlighted including vaccine status, antibody level (IgG) against Sars-CoV-2 prior to and following transplant. Organ function is reported and complications. Induction agent using non-depleting agent recorded. Informed consent obtained for covid+ organ. Infectious disease consultation. IgG antibody level check prior to transplant, and post transplant.

*Results: Two cases reported. Both had no complications related to covid. Excellent donors with KDPI <30. Cycle threshold 16 and above. Sequence 193 and 225. EPTS >85. Simulect and steroids used in both cases. Cold time short >16 hours. Both brain dead donors. LOS 7 and 8 days. PRA 0%. Donor blood group A and O. DGF in one recipient which recovered after 2 weeks see figure. The recipients had initially high antibody level which declined post transplant by 50%. See fig.

*Conclusions: Using Sars-CoV-2 donors is safe and provides a source of potential high quality organs in US Veterans who are generally underserved using informed consent. Full vaccination in recipient is a prerequisite.

« Back to 2022 American Transplant Congress